Drug Approval | October 01, 2025
Lupin receives FDA approval Rivaroxaban for oral suspension
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
Subscribe To Our Newsletter & Stay Updated
